Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

IMP3 expression in NSCLC brain metastases demonstrates its role as a prognostic factor in non-neuroendocrine phenotypes.

Del Gobbo A, Morotti A, Colombo AE, Vaira V, Ercoli G, Pesenti C, Bonaparte E, Guerini-Rocco E, Di Cristofori A, Locatelli M, Palleschi A, Ferrero S.

Med Oncol. 2017 Dec 1;35(1):2. doi: 10.1007/s12032-017-1062-7.

PMID:
29209838
2.

Insulin-like growth factor II-messenger RNA-binding protein-3 and lung cancer.

Findeis-Hosey JJ, Xu H.

Biotech Histochem. 2012 Jan;87(1):24-9. doi: 10.3109/10520295.2011.591831. Epub 2011 Aug 15. Review.

PMID:
21838610
3.

The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung.

Del Gobbo A, Vaira V, Guerini Rocco E, Palleschi A, Bulfamante G, Ricca D, Fiori S, Bosari S, Ferrero S.

J Thorac Oncol. 2014 Nov;9(11):1656-61. doi: 10.1097/JTO.0000000000000316.

4.

IMP3 can predict aggressive behaviour of lung adenocarcinoma.

Beljan Perak R, Durdov MG, Capkun V, Ivcevic V, Pavlovic A, Soljic V, Peric M.

Diagn Pathol. 2012 Nov 28;7:165. doi: 10.1186/1746-1596-7-165.

5.

IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.

Massironi S, Del Gobbo A, Cavalcoli F, Fiori S, Conte D, Pellegrinelli A, Milione M, Ferrero S.

Endocrine. 2017 Nov;58(2):360-367. doi: 10.1007/s12020-017-1249-x. Epub 2017 Feb 17.

PMID:
28210937
6.

Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA).

Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, Sneed P, Boyle J, Kirkpatrick JP, Mak KS, Shih HA, Engelman A, Roberge D, Arvold ND, Alexander B, Awad MM, Contessa J, Chiang V, Hardie J, Ma D, Lou E, Sperduto W, Mehta MP.

JAMA Oncol. 2017 Jun 1;3(6):827-831. doi: 10.1001/jamaoncol.2016.3834.

7.

IMP3 Immunohistochemical Expression Remains Consistent Among All Grades of Gastrointestinal Neuroendocrine Tumors.

Agostini-Vulaj D, Whitney-Miller CL, Gonzalez RS, McMahon LA, Findeis-Hosey JJ.

Appl Immunohistochem Mol Morphol. 2018 Apr;26(4):288-293. doi: 10.1097/PAI.0000000000000416.

PMID:
27438513
8.

IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.

Yan J, Wei Q, Jian W, Qiu B, Wen J, Liu J, Fu B, Zhou X, Zhao T.

Lung. 2016 Feb;194(1):137-46. doi: 10.1007/s00408-015-9829-0. Epub 2015 Nov 25.

PMID:
26608347
9.

Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma.

Saad AG, Yeap BY, Thunnissen FB, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR.

Cancer. 2008 Oct 15;113(8):2129-38. doi: 10.1002/cncr.23826.

10.

Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.

Chromecki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, Shariat SF.

BJU Int. 2012 Jul;110(1):63-8. doi: 10.1111/j.1464-410X.2011.10703.x. Epub 2011 Nov 11.

11.

CIP4 promotes lung adenocarcinoma metastasis and is associated with poor prognosis.

Truesdell P, Ahn J, Chander H, Meens J, Watt K, Yang X, Craig AW.

Oncogene. 2015 Jul;34(27):3527-35. doi: 10.1038/onc.2014.280. Epub 2014 Sep 1.

12.

Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma.

Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM.

Ann Surg Oncol. 2009 Jun;16(6):1711-9. doi: 10.1245/s10434-009-0446-0. Epub 2009 Apr 9.

PMID:
19357927
13.

Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.

Pelosi G, Pasini F, Sonzogni A, Maffini F, Maisonneuve P, Iannucci A, Terzi A, De Manzoni G, Bresaola E, Viale G.

Cancer. 2003 May 15;97(10):2487-97.

14.

Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer.

Enders F, Geisenberger C, Jungk C, Bermejo JL, Warta R, von Deimling A, Herold-Mende C, Unterberg A.

Clin Neurol Neurosurg. 2016 Mar;142:72-80. doi: 10.1016/j.clineuro.2016.01.011. Epub 2016 Jan 14.

PMID:
26816105
15.

[Expression of insulin-like growth factor 2 mRNA-binding protein 3 expression and analysis of prognosis in the patients with lung squamous cell carcinoma].

Lin L, Zhang J, Wang Y, Zheng L, Lin Z, Cai Y.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Jul;29(7):694-7. Chinese.

PMID:
23837977
16.

Impact of non-small cell lung cancer histology on survival predicted from the graded prognostic assessment for patients with brain metastases.

Guo S, Reddy CA, Chao ST, Suh JH, Barnett GH, Vogelbaum MA, Videtic GM.

Lung Cancer. 2012 Aug;77(2):389-93. doi: 10.1016/j.lungcan.2012.03.028. Epub 2012 Apr 27.

PMID:
22542706
17.

Prognostic effect of intratumoral neutrophils across histological subtypes of non-small cell lung cancer.

Rakaee M, Busund LT, Paulsen EE, Richardsen E, Al-Saad S, Andersen S, Donnem T, Bremnes RM, Kilvaer TK.

Oncotarget. 2016 Nov 1;7(44):72184-72196. doi: 10.18632/oncotarget.12360.

18.

AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases.

Wu X, Ma W, Zhou Q, Yan H, Lim ZF, Huang M, Deng C, Yu X, Su H, Komo S, Yang H, Zhang X, Wen S, Zhang Z, Ma PC.

J Cancer Res Clin Oncol. 2017 Oct;143(10):1947-1957. doi: 10.1007/s00432-017-2408-4. Epub 2017 May 27.

19.
20.

Determinants of survival in advanced non--small-cell lung cancer in the era of targeted therapies.

Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans T, Langer C.

Clin Lung Cancer. 2013 Sep;14(5):581-91. doi: 10.1016/j.cllc.2013.05.002. Epub 2013 Jul 1.

Supplemental Content

Support Center